Abstract
Introduction
Mutations in the epidermal growth factor receptor (EGFR) have been reported as predictive markers of tumour response to tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Although the “common” EGFR mutations have been associated with response to EGFR-TKIs, the correlation with response to treatment for many other rare mutations is still unclear. The aim of this study was to investigate the clinical significance of rare and complex mutations, and the efficacy of EGFR-TKIs in this selected group of patients.
Methods
Three hundred and thirty patients with stage IIIB/IV NSCLC (106 females aged 62.5 ± 1.1 years; 224 males aged 68.0 ± 0.6 years) were enrolled in the study. Formalin fixed paraffin embedded tissue samples were screened for mutations using a high resolution melting technique, followed by Sanger sequencing of exons 18-21 of the EGFR-gene. Mutation status was also tested using the Roche Cobas® EGFR mutation test.
Results
EGFR mutations were detected in 31 tumours (9.4 %). Eleven cases carried novel mutations, six of these patients were treated with erlotinib or gefitinib. A response rate (RR) of 50.0 % was obtained in the group with rare EGFR mutations, the PFS was 3.0 months [standard deviation (STD) = 5.4 months]. The RR to EGFR-TKIs in patients with conventional EGFR mutations was 85 % with a median PFS of 10.5 months (STD = 3.6 months).
Conclusion
We reported six patients with rare EGFR mutations of unknown clinical significance and their association with EGFR-TKIs. Report of cases harbouring rare mutations can support the decision making progress in this subset of patients.
This is a preview of subscription content, log in via an institution to check access.
References
Shigematsu H, Lin L, Takahashi T, et al. Clinical course of patients with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–46.
Ferlay J. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.
Mok TS, Wu YL, Thonprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.
Pallis AG, Voutsina A, Kalikaki A, et al. ‘Classical’ but no ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer. 2007;17:3812–21.
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol. 2010;11:121–8.
Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:839–44.
Wu JY, Yu CJ, Yang CH, et al. First-or second-line therapy with gefitinib produces equal survival in non small cell lung cancer. Am J Respir Crit Care Med. 2008;178:847–53.
Murray S, Dahabreh IJ, Linardou H, et al. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKI in non small cell lung cancer: an analytical database. J Thorac Oncol. 2008;3:832–9.
Gu D, Scaringe WA, Li K, et al. Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Human Mutat. 2007;28:760–70.
De Pas T, Toffalorio F, Manzotti M, et al. Activity of Epidermal growth factor receptor tyrosine kinas inhibitors in patients with non small cell lung cancer harbouring rare epidermal growth factor receptor mutations. J Thorac Oncol. 2011;6:1895–901.
Ceteno I, Blay P, Santamaria I, et al. Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncgenesis: a novel germ line mutation in EGFR detected in a patient with lung adenocarcinoma. BMC Cancer. 2011;11:172.
Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–85.
Do H, Krypuy M, Mitchell P, et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer. 2008;8:142.
Heideman D, Thunnissen F, Doeleman M, et al. A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell Oncol. 2009;31:329–33.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guiline (version 1.1). Eur J Cancer. 2009;2:228–47.
Vallières E, Shepherd FA, Crowley J, et al. The IASLC lung cancer staging project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;2009(4):1049–59.
Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer—search and destroy. Eur J Cancer. 2006;42:17–23.
Hiesh MH, Fang YF, Chang WC, et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer. 2006;53:311–22.
Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol. 2005;23:6829–37.
Ichihara S, Toyooka S, Fujiwara Y, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small cell lung cancer. Int J Cancer. 2007;120:1239–47.
De Vries NA, Buckle T, Zhao J, et al. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transportersP-gp and BCRP. Invest New Drugs. 2012;30:443–9.
Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790 M mutations in epidermal growth factor receptor mutatant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12:6494–501.
Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer. 2010;69:272–8.
Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007;97:778–84.
Rios FL, Angulo B, Gomez B, et al. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol. 2013;66:381–5.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
MO, ID, ED, FD, JV, EDL and JB have no conflicts of interest to report.
Funding
MO, ID, ED, FD, JV, EDL and JB have no sources of funding to report.
Ethical approval and informed consent
The authors state that this study was performed with full respect for individuals’ rights to confidentiality and in accordance with procedures supervised by local authorities responsible for ethical research.
Rights and permissions
About this article
Cite this article
Oyaert, M., Demedts, I., Boone, E. et al. Antitumoral Activity of Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harbouring Rare Epidermal Growth Factor Receptor Mutations. Mol Diagn Ther 19, 267–272 (2015). https://doi.org/10.1007/s40291-015-0158-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40291-015-0158-z